Page 70 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =Stereotactic radiotherapy (SRT) for central lung tumors: the experience of Florence University-Careggi Hospital RadiotherapyM. PERNA1, V. SCOTTI1, V. DI CATALDO2, G. SIMONTACCHI1, M. CASATI1, A. BRUNI3, A. TURKAJ1, G. A. CARTA1, C. BECHERINI1, C.E. COMIN4, K. FERRARI5, B. AGRESTI1, C. DE LUCA CARDILLO1, L. MASI2, R. DORO2, S. PALLOTTA1, L. LIVI11Universitaria Careggi, University of Florence, Florence, Italy.Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-2 CyberKnife Center- I.F.C.A (Istituto Fiorentino di Cura ed Assistenza), University of Florence, Florence, Italy.3 Radiation Oncology Department, Azienda Ospedaliero Universitaria "Policlinico" di Modena, Modena4Histopathology and Molecular Pathology, University of FlorenceDepartment of experimental and clinical medicine, Section of Surgery,5 Pneumonology and Thoracic Phisiopathology Unit, Cardiothoracic Department, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyIntroductionStereotactic body radiotherapy (SBRT) for central lung tumors, defined as tumor within 2 cm or touching the zone of the proximal bronchial tree or tumors immediately adjacent to the mediastinal or pericardial pleura (Adebahr S. et al. BJR 2015) is debated because of toxicities to organs at risk. No evidences from phase III trial are available.61